Benefitting Rutledge Cancer Foundation

An Evening with RCF - Finding a Cure: Providing Hope for Young Cancer Patients

Honoring Dr. Greg Aune, MD, PhD

Support our mission with a RCF Childhood Cancer Awareness Butterfly Yard Sign

Every $100+ donation during the month of September will receive a RCF Childhood Cancer Awareness Butterfly Yard Sign to help raise awareness of Childhood Cancer in our community. Yard Signs will be delivered within a 25 mile radius of our Fort Worth office.

*Signs are included with all evening with RCF sponsorships*

RCF's research team awarded 2-year NIH grant to support ongoing collaboration with research facilities across Texas

On April 1, 2021, a grant from National Institute of Health (NIH), in a combined effort with the National Heart Lung and Blood Institute, was awarded to a collaborative project led by Rutledge Cancer Foundation with Co-Principal Investigators Gregory Aune, MD, PhD of UT Health/ GCCRI of San Antonio, Texas and Jason Yustein, MD, PhD of the Faris D. Virani Ewing Sarcoma Center at the Baylor College of Medicine in Houston, Texas.

The award supports an ongoing effort initiated by the Rutledge Cancer Foundation in collaboration with Qana Therapeutics (Austin, Texas), Greehey Children’s Cancer Research Institute (GCCRI, San Antonio, Texas), Baylor College of Medicine (Houston, Texas) and UNT Health Science Center (Fort Worth, Texas), which aims to develop novel treatments for Ewing sarcoma with minimal side effects, especially cardiovascular. 

The team will utilize novel nanoparticle technology funded by Rutledge Cancer Foundation and developed by Qana Therapeutics and Dr. Andras Lacko of UNT Health Science Center, to selectively deliver novel cytotoxic chemotherapies directly to Ewing sarcoma tumors with high expression of SR-B1, which is a receptor or protein that is located on the surface of the tumor cell.

More importantly, preliminary studies in the lab have shown little to no cardiac toxicity in young mice.

During the two-year grant, the team hopes to generate critical data needed for early phase patient clinical trials. Additionally, the plan is to further develop this approach utilizing next generation therapies, such as small molecules and nucleic acids, to treat sarcomas and other solid tumor cancers more effectively with less toxicity. 

What does this mean for Ewing sarcoma patients? 

Ewing sarcoma’s 40-year-old chemotherapy regimen remains a significant contributor to mortality and long-term cardiovascular complications in adolescent and young adult cancer patients. The goal of this project is to bring less toxic, more curative cancer treatments to pediatric and young adult patients.

Gregory Aune, MD, PhD, UT Health/ GCCRI

Jason Yustein, MD, PhD, Baylor College of Medicine

Jim Graham, CEO, Qana Therapeutics

Laura Rutledge, Executive Director, Rutledge Cancer Foundation

In Loving Memory

Wyatt Donahue

1993 - 2021

Lawson Penny

1989 - 2021

RCF Cancer Fighting T-shirt Now Available

Looking for a great stocking stuffer and want to find a way to give back? Purchase your RCF t-shirt today and all proceeds will go towards critical patient programming and research for young adult cancer patients across North Texas. 

The Rutledge Cancer Foundation Works To Ease The Impact Of Cancer On The Lives Of Teens And Young Adults, Raise Survival Rates And Find A Cure For Sarcomas And Other Solid Tumor Cancers.

Ease The Impact

We want to make life after cancer easier for young people

Learn How ▸

Raise The Rate

We want to raise cancer survival rates through education and early detection

Learn How ▸

Find The Cure

We support research for less toxic, personalized cancer therapies

Learn How ▸

Recent Newsletters

Community Events

Patient Events

Third-Party Events